Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.BACKGROUND
 GUIDE is a phase IIIb randomized, double-blind, parallel-group, multicentre study of adults with moderate-to-severe plaque psoriasis. 
GUIDE
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.BACKGROUND
 Guselkumab is an interleukin (IL)-23 inhibitor with demonstrated efficacy in patients with psoriasis.


 Evaluate the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis.  In study part 1, patients with a short disease duration (SDD [≤2 years]) or a long disease duration (LDD [>2 years]) received guselkumab 100 mg at Week (W) 0, 4, 12, 20 and 28.  Guselkumab rapidly decreased these markers of systemic inflammation across all patient groups analysed at W4.  Guselkumab was well tolerated.


 Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. 
guselkumab